SCYNEXIS Valuation
Is 135A undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 135A when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 135A (€1.16) is trading below our estimate of fair value (€43.66)
Significantly Below Fair Value: 135A is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 135A?
Key metric: As 135A is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is 135A's PS Ratio? | |
|---|---|
| PS Ratio | 5.6x |
| Sales | US$8.57m |
| Market Cap | US$47.06m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | n/a |
| Enterprise Value/EBITDA | n/a |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does 135A's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 11.8x | ||
93M1 MPH Health Care | 0.9x | -60.2% | €102.8m |
0RX Redx Pharma | 13.3x | -37.6% | €65.0m |
HIGH Cantourage Group | 29.5x | 38.6% | €57.9m |
2FJ0 Pierrel | 3.4x | n/a | €92.8m |
135A SCYNEXIS | 5.6x | 30.8% | €47.1m |
Price-To-Sales vs Peers: 135A is good value based on its Price-To-Sales Ratio (5.6x) compared to the peer average (11.8x).
Price to Sales Ratio vs Industry
How does 135A's PS Ratio compare vs other companies in the European Pharmaceuticals Industry?
| 24 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| 24 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Sales vs Industry: 135A is expensive based on its Price-To-Sales Ratio (5.6x) compared to the European Pharmaceuticals industry average (2.9x).
Price to Sales Ratio vs Fair Ratio
What is 135A's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 5.6x |
| Fair PS Ratio | 1.2x |
Price-To-Sales vs Fair Ratio: 135A is expensive based on its Price-To-Sales Ratio (5.6x) compared to the estimated Fair Price-To-Sales Ratio (1.2x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | €1.16 | €6.17 +431.8% | 14.1% | €7.41 | €5.56 | n/a | 3 |
| Nov ’25 | €1.23 | €6.04 +390.5% | 14.1% | €7.25 | €5.43 | n/a | 3 |
| Oct ’25 | €1.31 | €6.04 +360.6% | 14.1% | €7.25 | €5.43 | n/a | 3 |
| Sep ’25 | €1.31 | €6.29 +381.3% | 13.0% | €7.32 | €5.49 | n/a | 4 |
| Aug ’25 | €1.93 | €6.34 +228.5% | 13.0% | €7.38 | €5.54 | n/a | 4 |
| Jul ’25 | €1.83 | €6.36 +248.5% | 13.0% | €7.40 | €5.55 | n/a | 4 |
| Jun ’25 | €2.13 | €6.40 +200.4% | 13.0% | €7.45 | €5.58 | n/a | 4 |
| May ’25 | €1.67 | €6.40 +283.9% | 13.0% | €7.45 | €5.58 | n/a | 4 |
| Apr ’25 | €1.31 | €6.40 +390.1% | 13.0% | €7.45 | €5.59 | n/a | 4 |
| Mar ’25 | €1.47 | €6.51 +342.2% | 10.4% | €7.31 | €5.48 | n/a | 4 |
| Feb ’25 | €1.89 | €6.51 +244.0% | 10.4% | €7.31 | €5.48 | n/a | 4 |
| Jan ’25 | €2.03 | €7.49 +269.1% | 14.0% | €9.22 | €6.46 | n/a | 4 |
| Dec ’24 | €1.51 | €7.49 +395.6% | 14.0% | €9.22 | €6.46 | n/a | 4 |
| Nov ’24 | €1.75 | €9.42 +439.7% | 27.2% | €14.28 | €7.14 | €1.23 | 5 |
| Oct ’24 | €2.14 | €9.42 +341.4% | 27.2% | €14.28 | €7.14 | €1.31 | 5 |
| Sep ’24 | €3.19 | €10.82 +239.2% | 22.4% | €13.76 | €8.25 | €1.31 | 5 |
| Aug ’24 | €2.66 | €10.45 +293.0% | 26.4% | €13.76 | €7.34 | €1.93 | 5 |
| Jul ’24 | €2.76 | €10.45 +279.4% | 26.4% | €13.76 | €7.34 | €1.83 | 5 |
| Jun ’24 | €2.30 | €10.45 +355.5% | 26.4% | €13.76 | €7.34 | €2.13 | 5 |
| May ’24 | €2.75 | €10.45 +280.1% | 26.4% | €13.76 | €7.34 | €1.67 | 5 |
| Apr ’24 | €2.64 | €10.27 +288.7% | 28.5% | €13.75 | €7.34 | €1.31 | 5 |
| Mar ’24 | €1.38 | €10.02 +625.0% | 34.1% | €14.18 | €6.62 | €1.47 | 5 |
| Feb ’24 | €1.67 | €14.98 +799.1% | 54.8% | €29.97 | €6.99 | €1.89 | 5 |
| Jan ’24 | €1.35 | €14.98 +1,011.9% | 54.8% | €29.97 | €6.99 | €2.03 | 5 |
| Dec ’23 | €2.00 | €14.98 +649.2% | 54.8% | €29.97 | €6.99 | €1.51 | 5 |
| Nov ’23 | €2.31 | €18.06 +683.3% | 56.5% | €30.11 | €7.02 | €1.75 | 5 |
Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.
Discover undervalued companies
Amneal Pharmaceuticals
US$2.6b
Develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide.
2DT
US$7.55
7D
2.0%
1Y
95.6%
Collegium Pharmaceutical
US$993.0m
A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.
354
US$29.20
7D
5.0%
1Y
23.7%
Pharming Group
€478.2m
A biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally.
PHGN
€0.72
7D
1.8%
1Y
-31.2%